Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 6/20 | 0.51 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.51 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.51 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.49 |
| ▸ | DRD3 | P35462 | 1/20 | 0.49 |
| ▸ | ASIC3 | Q9UHC3 | 1/20 | 0.47 |
| ▸ | CD44 | P16070 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.45 |
| ▸ | HTR2C | P28335 | 1/20 | 0.45 |
| ▸ | HTR2B | P41595 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10203261 | 0.86 | PNMT (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL29808272 | 0.86 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL183621 | 0.86 | ASIC3 (0.60) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL1000239 | 0.84 | ASIC3 (0.59) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL14100824 | 0.80 | PNMT (0.49) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL1431297 | 0.79 | ASIC3 (0.55) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL329770 | 0.79 | ASIC3 (0.69) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| Hydrochloric Acid SCHEMBL1000104 | 0.77 | ASIC3 (0.68) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL2675790 | 0.77 | ASIC3 (0.67) | PNMTADRA2AADRA2BADRA2CDRD2 | |
| SCHEMBL25273345 | 0.76 | ASIC3 (0.51) | PNMTADRA2AADRA2BADRA2CDRD2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CHEMOCENTRYX, INC. | 2020-04-23 | — | — | US | disclosed |
| US-9783540-B2 | Substituted tetrahydropyrans as CCR2 modulators | CHEMOCENTRYX, INC. (US) | 2017-10-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200121688-A1 | SUBSTITUTED TETRAHYDROPYRANS AS CCR2 MODULATORS | CCR2, CCR1, CCR5 | PNMT 2379/4885ADRA2A 164/4885ADRA2B 177/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.